Tadalafil
Astrocytoma, Grade III
Washington University School of MedicineSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Astrocytoma, Grade III cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olutasidenib Rigel Pharmaceuticals | Phase 2 | CCC |
BMX-001 FREE BASE BioMimetix JV, LLC | Phase 1/2 | CCC |
Heat Shock Protein Peptide Complex-96 Ann & Robert H Lurie Children's Hospital of Chicago | Phase 1 | CC |
Debio 0123 Debiopharm International SA | Phase 1/2 | CC |
Zotiraciclib European Organisation for Research and Treatment of Cancer - EORTC | Phase 1 | CC |
Same molecule, other indications
Tadalafil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →